Vanda Pharmaceuticals Inc.
VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment ofā¦ read more
Healthcare
Biotechnology
19 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.75
Price+1.20%
$0.08
1Y
Price
Market Cap
$398.879m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-52.0%
EBITDA Margin-40.1%
Net Profit Margin-56.5%
Free Cash Flow MarginRevenue
$212.074m
+6.7%
1y CAGR-4.8%
3y CAGR-4.9%
5y CAGREarnings
-$84.199m
-345.5%
1y CAGR-419.6%
3y CAGR-335.0%
5y CAGREPS
-$1.42
-343.7%
1y CAGR-435.8%
3y CAGR-347.1%
5y CAGRBook Value
$465.999m
$601.140m
Assets$135.141m
Liabilities$6.227m
DebtDebt to Assets
1.0%
-0.1x
Debt to EBITDAFree Cash Flow
-$82.952m
-410.6%
1y CAGR-233.9%
3y CAGR-188.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company